Skip to main content

Table 2 Percentage (with 95% confidence intervals) of subjects reporting solicited local (injection site) symptoms within 7 days after the first and after the second dose of H1N1 vaccine in adults aged 18 to 60 years and in adults >60 years

From: Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial

Symptom Intensity Group A Vaccinated on Day 0 and Day 21 Group B Vaccinated on Day 0 and Day 182
Dose 1% (95% CI)
18-60 years N = 92 >60 years N = 90 18-60 years N = 70 >60 years N = 52
Pain Any 94.6 78.9 95.7 67.3
(87.8-98.2) (69.0-86.8) (88.0-99.1) (52.9-79.7)
Grade 3* 0.0 2.2 0.0 0.0
(0.0-3.9) (0.3-7.8) (0.0-5.1) (0.0-6.8)
Redness Any 10.9 8.9 11.4 1.9
(5.3-19.1) (3.9-16.8) (5.1-21.3) (0.0-10.3)
>100 mm 0.0 0.0 0.0 0.0
(0.0-3.9) (0.0-4.0) (0.0-5.1) (0.0-6.8)
Swelling Any 12.0 6.7 8.6 1.9
(6.1-20.4) (2.5-13.9) (3.2-17.7) (0.0-10.3)
>100 mm 0.0 0.0 0.0 0.0
(0.0-3.9) (0.0-4.0) (0.0-5.1) (0.0-6.8)
   Dose 2% (95% CI)
18-60 years N = 91 >60 years N = 85 18-60 years N = 60 >60 years N = 45
Pain Any 87.9 72.9 90.0 57.8
(79.4-93.8) (62.2-82.0) (79.5-96.2) (42.2-72.3)
Grade 3* 2.2 0.0 5.0 0.0
(0.3-7.7) (0.0-4.2) (1.0-13.9) (0.0-7.9)
Redness Any 6.6 12.9 10.0 6.7
(2.5-13.8) (6.6-22.0) (3.8-20.5) (1.4-18.3)
>100 mm 0.0 0.0 3.3 2.2
(0.0-4.0) (0.0-4.2) (0.4-11.5) (0.1-11.8)
Swelling Any 8.8 11.8 16.7 8.9
(3.9-16.6) (5.8-20.6) (8.3-28.5) (2.5-21.2)
>100 mm 0.0 0.0 0.0 0.0
(0.0-4.0) (0.0-4.2) (0.0-6.0) (0.0-7.9)
  1. *Grade 3 was defined as significant injection site pain at rest which prevents normal activities (inability to attend/do work).